Takeda Pharmaceutical Co Ltd ADR (TAK)
Takeda Pharmaceutical Co Ltd ADR is a depositary receipt listed on the New York Stock Exchange that represents common stock of Takeda Pharmaceutical Company Limited. The underlying issuer is a global pharmaceutical company based in Tokyo, Japan, with operations spanning Japan and international markets. Its business covers the research, development, manufacturing, marketing, and out-licensing of medicines across gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. Takeda’s portfolio includes products such as Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Dexilant, Adynovate/Adynovi, Takhzyro, Livtencity, FRUZAQLA, Ninlaro, Velcade, QDENGA, and Alunbrig, among others. The company also maintains a range of in-licensing, collaboration, and licensing arrangements with biotechnology and pharmaceutical partners, supporting its research and development activities.
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-TAK
|
$15.36
|
-10.5% Downside
|
Fair
|
$20.97
|
22.2% Upside
|
Undervalued
|
Good
|
—
|
—
|
0.4923
|
2.8%
|
July 30, 2026
|
-57.6x
|
1.2x
|
1.9x
|
53.952 B
|
86.059 B
|
38.7%
|
99.9%
|
5.5
|
-204.7%
|
-567.9%
|
